Improving lung recovery after severe blood loss
Improvement of Organ Function after Severe Hypovolemia
['FUNDING_R01'] · FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH · NIH-11249607
Aims to find ways to stop harmful signals that cause life‑threatening lung damage after severe blood loss or shock.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH (nih funded) |
| Locations | 1 site (MANHASSET, UNITED STATES) |
| Trial ID | NIH-11249607 on ClinicalTrials.gov |
What this research studies
This research looks at a molecule called eCIRP that is released after major blood loss and can drive dangerous lung inflammation. Scientists are studying blood and tissue samples from people and animals and doing lab work with cells to see how eCIRP gets out of cells and turns on an inflammatory pathway called STING. They are testing whether blocking the pore-forming protein gasdermin D or the STING/type I interferon pathway can prevent lung injury. The goal is to translate those findings into treatments that reduce inflammation and improve survival after hemorrhagic shock.
Who could benefit from this research
Good fit: Patients who have experienced severe hemorrhagic shock or major traumatic blood loss and are at risk for or developing acute lung injury would be most relevant to this work.
Not a fit: People without recent major blood loss, trauma, or risk of acute lung injury are unlikely to benefit directly from this specific research.
Why it matters
Potential benefit: If successful, the work could lead to new treatments that prevent or lessen acute lung injury after severe bleeding or shock.
How similar studies have performed: Early animal and lab studies support the role of eCIRP, gasdermin D, and STING in inflammation, but translating these findings into human therapies is still largely unproven.
Where this research is happening
MANHASSET, UNITED STATES
- FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH — MANHASSET, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WANG, PING — FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
- Study coordinator: WANG, PING
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acute Lung Injury, Acute Pulmonary Injury